生命科学资讯

Novartis signs macrocyclic deal with Unnatural Products for $100M upfront

Reversal on Moderna's flu application follows atypical path through FDA

Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results

Faeth goes public in merger with Sensei, nets $200M in stock sale

FDA reverses course, will review Moderna’s flu vaccine

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

Paragon's new biotech Korsana tackles Alzheimer's like Roche

Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News

Leo Pharma says it's turned a profit for the first time in seven years

Moderna faces setback in Arbutus' mRNA patent fight

Unlocking health data

FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher

Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters

Compass Pathways soars on second Phase 3 depression hit

Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink

Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

Gilead gets cancer drug from China-based Genhouse for $80M upfront

Pentagon adds, then withdraws, WuXi AppTec to Chinese military list

Lilly appeals retatrutide classification ruling in case that could impact compounders